# Omega™ Left Atrial Appendage (LAA) Occluder in Patients With Non-Valvular Atrial Fibrillation

> **NCT03526471** · NA · COMPLETED · sponsor: **Vascular Innovations Co. Ltd.** · enrollment: 20 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DEVICE:** Omega™ Left Atrial Appendage (LAA) Occluder

## Key facts

- **NCT ID:** NCT03526471
- **Lead sponsor:** Vascular Innovations Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-01
- **Primary completion:** 2020-01-30
- **Final completion:** 2020-03-31
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2020-08-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03526471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03526471, "Omega™ Left Atrial Appendage (LAA) Occluder in Patients With Non-Valvular Atrial Fibrillation". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT03526471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*